{"id":9203,"date":"2025-11-15T09:19:15","date_gmt":"2025-11-15T06:19:15","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9203"},"modified":"2025-11-15T09:19:15","modified_gmt":"2025-11-15T06:19:15","slug":"one-time-gene-editing-therapy-ctx310-a-new-frontier-in-lipid-management","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/one-time-gene-editing-therapy-ctx310-a-new-frontier-in-lipid-management\/","title":{"rendered":"One-Time Gene-Editing Therapy CTX310: A New Frontier in Lipid Management"},"content":{"rendered":"
One-Time Gene-Editing Therapy CTX310: A New Frontier in Lipid Management<\/div>\n
<\/div>\n
Source: AHA Scientific Sessions 2025 \u2014 Published in NEJM (2025)<\/div>\n
<\/div>\n
A Revolutionary, First-of-its-kind\u00a0 (first-in-human study) presented at the American Heart Association Scientific Sessions 2025 and simultaneously published in the New England Journal of Medicine (NEJM, 2025) has revealed unprecedented results for CTX310, A potentially once-in-a-lifetime, one-and-done\u00a0 intravenous gene-editing therapy.<\/div>\n
The therapy permanently switches off the gene ANGPTL3 (Angiopoietin-like protein 3)\u2014a key regulator of triglycerides and LDL cholesterol.<\/div>\n
<\/div>\n
Keynotes:<\/div>\n
1.\u2060 \u2060Study Overview<\/div>\n
1. The therapy CTX310 uses in vivo gene editing to disable the ANGPTL3 gene. (ANGPTL3 = main liver gene controlling triglycerides + LDL).<\/span><\/div>\n
2. 15 high-risk patients with severe lipid disorders received one single IV dose.<\/span><\/div>\n
3. The study was funded by CRISPR Therapeutics and conducted at leading U.S. centers.<\/span><\/div>\n
<\/div>\n
2.\u2060 \u2060Key Findings (Unprecedented Results)<\/div>\n
1. LDL cholesterol dropped sharply within 2 weeks, sustained for \u2265 60 days.<\/span><\/div>\n
2. Triglycerides also decreased significantly during the same period.<\/span><\/div>\n
3. Every single patient in the trial experienced measurable lipid reduction.<\/span><\/div>\n
4. Lead author Dr. Luke Laffin described the results as: \u201ctruly unprecedented.\u201d<\/span><\/div>\n
5. Senior author Dr. Steven Nissen emphasized the importance of \u201cone-and-done\u201d therapy for lifelong lipid disorders.<\/span><\/div>\n
<\/div>\n
3.\u2060 \u2060Mechanism of Action :<\/div>\n
1. Statins \u2192 Block cholesterol synthesis \u2192 Daily use for life.<\/span><\/div>\n
2. PCSK9 inhibitors (Repatha, Praluent) \u2192 Prevent LDL-receptor degradation \u2192 Injections every 2\u20134 weeks.<\/span><\/div>\n
3. Inclisiran \u2192 Silences PCSK9 mRNA \u2192 Twice-yearly injection.<\/span><\/div>\n
4. CTX310 \u2192 Gene-editing to switch off ANGPTL3 (gene responsible for regulating LDL & triglycerides) \u2192<\/span><\/div>\n
Potentially permanent effect after a single dose.<\/div>\n
<\/div>\n
4.\u2060 \u2060Dosing Pattern Comparison<\/div>\n
1. Statins \u2013 Oral, daily for life.<\/span><\/div>\n
2. PCSK9 mAbs \u2013 Injection every 2\u20134 weeks.<\/span><\/div>\n
3. Inclisiran \u2013 Every 6 months.<\/span><\/div>\n
4. CTX310 \u2013 One IV infusion only (conceptually once per lifetime if long-term safety is confirmed).<\/span><\/div>\n
<\/div>\n
5.<\/div>\n
\u2e3b<\/div>\n
<\/div>\n
Strength of Lipid Reduction<\/div>\n
1. Statins:<\/span><\/div>\n
LDL \u2193 ~50\u201360% (baseline therapy).<\/div>\n
2. PCSK9 inhibitors (Repatha, Praluent):<\/span><\/div>\n
LDL \u2193 50\u201360% additional beyond statins \u2014 strongest potency available but limited by high cost and frequent injections.<\/div>\n
3. Inclisiran (Leqvio):<\/span><\/div>\n
LDL \u2193 ~50% total \u2014 adds ~10\u201315% beyond statins; major advantage is excellent adherence due to twice-yearly dosing.<\/div>\n
4. Ezetimibe:<\/span><\/div>\n
LDL \u2193 18\u201322% \u2014 safe, inexpensive, and provides a moderate add-on effect.<\/div>\n
5. Bempedoic Acid:<\/span><\/div>\n
LDL \u2193 15\u201320% \u2014 best option for statin intolerance because it is activated in the liver only (not the muscles); oral and well tolerated.<\/div>\n
6. CTX310 (Phase 1):<\/span><\/div>\n
\u2022 Strong reductions in LDL and triglycerides by Week 2.<\/span><\/div>\n
\u2022 Sustained for \u2265 60 days.<\/span><\/div>\n
\u2022 LDL \u2193 ~50% at the highest dose.<\/span><\/div>\n
\u2022 Triglycerides \u2193 ~55% at the highest dose.<\/span><\/div>\n
\u2022 Long-term durability still under investigation.<\/span><\/div>\n
<\/div>\n
6.\u2060 \u2060Adherence Advantages<\/div>\n
1. Statins: Poor adherence \u2014 50% stop within one year.<\/span><\/div>\n
2. PCSK9: Adherence depends on insurance and frequent injections.<\/span><\/div>\n
3. Inclisiran: Better adherence (twice yearly).<\/span><\/div>\n
4. CTX310:<\/span><\/div>\n
\u2022 Perfect theoretical adherence (one treatment only)<\/span><\/div>\n
\u2022 Solves decades-long adherence problems in lipid management.<\/span><\/div>\n
<\/div>\n
7.\u2060 \u2060Safety Profile<\/div>\n
1. Generally safe in early data.<\/span><\/div>\n
2. Study reported: 2 serious adverse events + 3 infusion-related reactions.<\/span><\/div>\n
<\/div>\n
8.\u2060 \u2060Who Might Benefit in the Future?<\/div>\n
1. Patients with lifelong severe lipid disorders.<\/span><\/div>\n
2. Very high-risk ASCVD patients uncontrolled on maximum therapy.<\/span><\/div>\n
3. Patients who cannot tolerate statins.<\/span><\/div>\n
4. Patients with major adherence issues where one-time therapy is ideal.<\/span><\/div>\n
<\/div>\n
Conclusion<\/div>\n
<\/div>\n
CTX310 represents the first real possibility of a single-dose, lifetime lipid treatment, targeting ANGPTL3 through permanent gene editing.<\/div>\n
If confirmed in larger trials, this therapy may reshape cardiovascular prevention and offer a transformative option for patients with severe lifelong dyslipidemia.<\/div>\n
<\/div>\n
https:\/\/professional.heart.org\/en\/meetings\/scientific-sessions\/<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

One-Time Gene-Editing Therapy CTX310: A New Frontier in Lipid Management Source: AHA Scientific Sessions 2025 \u2014 Published in NEJM (2025) A Revolutionary, First-of-its-kind\u00a0 (first-in-human study) presented at the American Heart Association Scientific Sessions 2025 and simultaneously published in the New England Journal of Medicine (NEJM, 2025) has revealed unprecedented results for CTX310, A potentially once-in-a-lifetime, […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9203","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9203"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9203\/revisions"}],"predecessor-version":[{"id":9204,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9203\/revisions\/9204"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}